NIFTY  8,938.55  0.34%
  SENSEX  28,890.30  0.45%
 CURRENCY  Rs  66.93/$ 70.86/€, 83.36/£
  GOLD  29,216.00  -0.29%
  SILVER  42,645.00  -0.45%
  DAX  11,967.50  1.18%
  FTSE  7,274.83  -0.34%
  CAC  4,888.76  0.41%
  HANG SENG  23,963.60  -0.76%
  NIKKEI  19,381.40  0.68%
  Shanghai Composite  3,253.33  0.23%
  DOW JONES  20,743.00  0.58%
  NASDAQ  5,865.95  0.47%
  S&P 500  2,365.38  0.60%
RAMCO SYSTEMS - Wins Contract Worth $2.5 Mn From Allegis Group For Cloud Svcs HOV SERVICES - Transaction Valued At $2.8 Bn

Another USFDA Alert For Ranbaxy

Video:

Play this video

September 24: Ranbaxy is in the spotlight again with global regulators starting to show concern. Reports suggest that the European and Australian regulators have sought information from the US FDA on company practices. Meanwhile, USFDA is looking into practices being followed at the Ohm facility in US, which is the only facility of Ranbaxy catering to the entire market now. We also trace the stock since the Daiichi Sankyo acquisition to where it stands right now.